Clinical Trial Update: Study of OFATUMUMAB as Part of the Scheme of Reduced Intensity Conditioning in High Risk Non-Hodgkin Lymphoma B Patients [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating OFATUMUMAB within a reduced intensity conditioning regimen for high-risk B-cell non-Hodgkin lymphoma patients; study completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• Ofatumumab (ofatumumab)

Snippet

Sponsor: Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea | Conditions: B-Cell Lymphomas | Phase 2 | Status: COMPLETED